ChromaDex Corporation with ticker code (CDXC) now have 5 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 9 and 7 with the average target price sitting at 7.9. With the stocks previous close at 5.28 this would indicate that there is a potential upside of 49.6%. The 50 day MA is 4.87 and the 200 day moving average is 4.84. The company has a market cap of $355m. You can visit the company’s website by visiting: http://www.chromadex.com
ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is headquartered in Los Angeles, California.